乙型肝炎抗病毒治疗中HBeAg水平变化对疗效的影响

谢志伟; 周福元

乙型肝炎抗病毒治疗中HBeAg水平变化对疗效的影响

南方医科大学南方医院感染内科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3281
- HTML全文浏览量: 8
- PDF下载量: 754
- 被引次数: 0
出版历程
- 出版日期: 2013-02-20

Influence of quantitative changes in HBeAg on the therapeutic efficacy of antiviral drugs

摘要

摘要:
乙型肝炎呈世界性流行,全世界共有3.5～4亿人感染乙型肝炎,其中我国占到全世界患病人数的1/4;每年约有100万人死于HBV感染相关疾病,因此乙型肝炎的有效治疗显得尤为重要。治疗过程中,HBeAg阴转或血清转换标志着乙型肝炎的复制能力与传染性下降以及良好的预后,而HBeAg的阴转或血清转换与HBeAg定量水平密切相关。
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 核苷类似物 /
- 干扰素ɑ
Abstract:
Hepatitis B remains a global epidemic threat to human health of the 350-400 million individuals worldwide infected with the hepatitis B virus (HBV) , one-quarter reside in China.Every year, an estimated one million people die from HBV-related diseases, making the development and institution of effective therapeutic strategies against HBV a global focus.Therapeutic efficacies are generally indicated by reduction or elimination of hepatitis B e antigen (HBeAg) , occurrence or enhancement of HBeAg seroconversion, or decreased levels of HBV DNA.While all of these effects are associated with a good prognosis, the elimination of HBeAg and event of HBeAg seroconversion have the strongest correlation with good prognosis.
- hepatitis B /
- chronic /
- hepatitis B e antigen /
- nucleosides analogues

HTML全文

参考文献(28)

[1]Liang X, Bi S, Yang W, et al.Epidemiological serosurvey ofhepatitis B in China-declining HBV prevalence due to hepati-tis B vaccination[J].Vaccine, 2009, 27 (47) :6550-6557.

[2]Lu FM, Zhuang H.Management of hepatitis B in China[J].Chin Med J (Engl) , 2009, 122 (1) :3-4.

[3]Fattovich G, Olivari N, Pasino M, et al.Long term outcomeof chronic hepatitis B in Caucasian patients:mortality after 25years[J].Gut, 2008, 57 (1) :84-90.

[4]Bortolotti F, Guido M, Bartolacci S, et al.Chronic hepatitis Bin children after e antigen seroclearance:final report of a 29-year longitudinal study[J].Hepatology, 2006, 43 (3) :556-562.

[5]Kao JH, Chen PJ, Lai MY, et al.Hepatitis B virus genotypesand spontaneous hepatitis B e antigen seroconversion in Tai-wanese hepatitis B carriers[J].J Medi Virol, 2004, 72 (3) :363-369.

[6]Fung SK, Lok AS.Hepatitis B viru genotypes:Do they play arole in the outcome of HBV infection?[J].Hepatology, 2004, 40 (4) :790-792.

[7]Janssen HL, van Zonneveld M, Senturk H, et al.Pegylatedinterferon alfa-2b alone or in combination with lamivudinefor HBeAg-positive chronic hepatitis B:a randomised trial[J].Lancet, 2005, 365 (9454) :123-129.

[8]Kao JH.Role of viral factors in the natural course and therapy ofchronic hepatitis B[J].Hepatol Int, 2007, 1 (4) :415-430.

[9]Jiang ZL, Zhou SX, Xie WX, et al.The correlation researchof the levels of HBeAg, HBV-DNA, concentrations of ADAand ALT in the serum from patients with chronic type B hepa-titis[J].Med Lab Sci Clin, 2007, 18 (3) :30-32. (in Chi-nese) 江志兰, 周少雄, 谢伟贤, 等.慢性乙肝患者血清HBeAg和HBV-DNA水平与ADA及ALT浓度的相关性研究[J].医学检验与临床, 2007, 18 (3) :30-32.

[10]Li L, He CQ, Liu J.Correlation analysis between hepatitis Bvirus DNA with HBeAg and ALT and its clinical significance[J].Lab Med Clin, 2011, 8 (7) :779-782. (in Chinese) 黎莉, 贺超奇, 刘军.慢性乙肝患者血清HBV DNA与HBeAg定量及ALT水平的相关性分析及临床意义[J].检验医学与临床, 2011, 8 (7) :779-782.

[11]Liang Y, Liang H, Liu YD.Correlation analysis between HBeAgand HBV DNA levels and ALT in patients with chronic hepatitis B[J].Shandong Med J, 2008, 48 (35) :92B. (in Chinese) 梁艳, 梁慧, 刘友德.慢性乙型肝炎患者HBeAg、ALT与HBV-DNA相关性探讨[J].山东医药, 2008, 48 (35) :92B.

[12]Li MH, Xie Y, Qiu GH, et al.The relationship of serum HB-sAg, HBeAg concentration and HBV-DNA load in chronichepatitis B during IFN treatment[J].Chin J Exp Clin Virol, 2011, 25 (1) :26-28. (in Chinese) 李明慧, 谢尧, 邱国华, 等.慢性乙型肝炎HBsAg, HBeAg和DNA变化的相关性研究[J].中华实验和临床病毒学杂志, 2011, 25 (1) :26-28.

[13]Hao YY, Xia J, Liu Y, et al.Prediction of HBeAg seroconver-sion to nucleos (t) ide analogues for hepatitis B e antigen-positive chronic hepatitis B using quantitative detection of on-treatment hepatitis B e antigen[J].Chin J Clin, 2012, 6 (11) :2915-2920. (in Chinese) 郝迎迎, 夏娟, 刘勇, 等.血清HBeAg定量检测对慢性乙型肝炎患者核苷 (酸) 类似物治疗后e抗原血清转换的预测作用[J].中华临床医师杂志, 2012, 6 (11) :2915-2920.

[14] Dai YF.Predictors of I-meAg seroconversion in chonic hep-atitis B patients treated with lamivudineJinan[J].Chin J Ce-liopathy, 2005, 5 (4) :246-248. (in Chinese) 戴元峰.拉米夫定治疗慢性乙肝病人的HBeAg血清转换的预测因素初探[J].中华腹部疾病杂志, 2005, 5 (4) :246-248.

[15]Zhang X, Lin SM, Ye F, et al.An early decrease in serumHBeAg titre is a strong predictor of virological response to en-tecavir in HBeAg-positive patients[J].J Viral Hepat, 2011, 18 (7) :e184-e190.

[16]Xie DY, Lin BL, Xu QH, et al.The predictive value of base-line HBeAg levels to the efficacy of 52 weeks treatment ofadefovir dipivoxil in patients with HBeAg-positive chronichepatitis B[J].Chin J Clin, 2010, 4 (8) :52-56. (in Chi-nese) 谢冬英, 林炳亮, 徐启桓, 等.基线HBeAg水平对HBeAg阳性慢性乙型肝炎阿德福韦酯治疗52周疗效的预测价值[J].中华临床医师杂志, 2010, 4 (8) :52-56.

[17]Huang J, Chen XP, Chen XF, et al.Study on the efficacyand HBeAg seroconversion related factors of telbivudinetherapy in HBeAg positive chronic hepatitis B[J].JChongqing Med Univ, 2011, 36 (7) , 849-853. (in Chi-nese) 黄晶, 陈小苹, 陈学福, 等.替比夫定治疗HBeAg阳性慢乙肝患者的HBeAg血清转换预测因素探讨[J].重庆医科大学学报, 2011, 36 (7) , 849-853.

[18]Sonneveld MJ, Zoutendijk R, Hansen BE, et al.Pegylated inter-feron results in higher serological, but not virological, responserates when compared to continuous entecavir[J].Antivir Ther, 2012, 17 (8) :1605-1608.

[19]Fried MW, Piratvisuth T, Lau GK, et al.HBeAg and hepatitisB virus DNA as outcome predictors during therapy withpeginterferon alfa-2a for HBeAg-positive chronic hepatitisB[J].Hepatology, 2008, 47 (2) :428-434.

[20]Zhu YY, Dong J, Chen YT, et al.Quantitative HBeAg assayas a predictive factor of HBeAg seroconversion induced byPEG-IFNα-2a therapy to HBeAg-positive chronic hepati-tis B[J].Chin J Gastroenterol Hepatol, 2010, 19 (10) :883-885. (in Chinese) 朱月永, 董菁, 陈攸涛, 等.e抗原定量对聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎抗原血清学转换的预测[J].胃肠病学和肝病学杂志, 2010, 19 (10) :883-885.

[21]Buster EH, Flink HJ, Simsek H, et al.Early HBeAg loss duringpeginterferonα-2b therapy predicts HBsAg loss:Results of along-term follow-up study in chronic hepatitis B patients[J].Am J Gastroenterol, 2009, 104 (10) :2449-2457.

[22]Tangkijvanich P, Komolmit P, Mahachai V, et al.Compari-son between quantitative hepatitis B surface antigen, hepati-tis B e-antigen and hepatitis B virus DNA levels for predic-ting virological response to pegylated interferon-a-2b ther-apy in hepatitis B e-antigen-positive chronic hepatitis B[J].Hepatol Res, 2010, 40 (4) :269-277.

[23]Ma H, Yang RF, Wei L.Quantitative serum HBsAg and HBeAgare strong predictors of sustained HBeAg seroconversion to pe-gylated interferon alfa-2b in HBeAg-positive patients[J].Gastroenterol Hepatol, 2010, 25 (9) :1498-1506.

[24]Hui CK, Leung N, Shek TW, et al.Sustained disease remis-sion after spontaneous HBeAg seroconversion is associatedwith reduction in fibrosis progression in chronic hepatitis BChinese patients[J].Hepatology, 2007, 46 (3) :690-698.

[25]Lin SM, Yu ML, Lee CM, et al.Interferon therapy in HBeAg-positive chronic hepatitis reduces progression to cirrhosisand hepatocellular carcinoma[J].J Hepatol, 2007, 46 (1) :45-52.

[26]Chu CM, Hung SJ, Lin J, et al.Natural history of hepatitisBe antigen to antibody seroconversion in patients with normalserum aminotransferase levels[J].Am J Med, 2004, 116 (12) :829-834.

[27]Peng J, Hou JL, Guo YB, et al.The impact of HBeAg statesand hepatitis B virus DNA loads on the prognosis of chronicsevere hepatitis B[J].Chin J Infect Dis, 2009, 27 (4) , 225-227. (in Chinese) 彭劼, 侯金林, 郭亚兵, 等.HBeAg状态及乙型肝炎病毒载量对慢性重型乙型肝炎预后的影响[J].中华传染病杂志, 2009, 27 (4) :225-227.

[28]Wu LP, Zhang JJ, Du RQ, et al.Comparative study on theclinical and pathological features of HBeAg negative/positivechronic hepatitis B patients[J].J Clin Hepatol, 2009, 25 (3) :175-177. (in Chinese) 吴丽萍, 张建军, 杜瑞清, 等.HBeAg阴性与阳性慢性乙型肝炎的临床病理对比研究[J].临床肝胆病杂志, 2009, 25 (3) :175-177.

施引文献

资源附件(0)

访问统计